In this study, type 2 diabetic patients taking Glucagon-like Peptide-1 Receptor Agonist (GLP-1RAs) have an initial 19% reduced glaucoma risk, increasing to a 29% reduction after 3 years.
Examples of GLP-1RAs include Exanatide (Byetta), Semaglutide (Ozempic), Liraglutide (Victoza, Saxenda), and Lixisenatide (Adlyxin).
No comments:
Post a Comment
Leave a Comment or Question: